Top

Published in:

Open Access 01-12-2010 | Review

Biomarkers in acute myocardial infarction

Authors: Daniel Chan, Leong L Ng

Published in: BMC Medicine | Issue 1/2010

Abstract

Myocardial infarction causes significant mortality and morbidity. Timely diagnosis allows clinicians to risk stratify their patients and select appropriate treatment. Biomarkers have been used to assist with timely diagnosis, while an increasing number of novel markers have been identified to predict outcome following an acute myocardial infarction or acute coronary syndrome. This may facilitate tailoring of appropriate therapy to high-risk patients. This review focuses on a variety of promising biomarkers which provide diagnostic and prognostic information.

Heart-type Fatty Acid Binding Protein and copeptin in combination with cardiac troponin help diagnose myocardial infarction or acute coronary syndrome in the early hours following symptoms. An elevated N-Terminal Pro-B-type Natriuretic Peptide has been well validated to predict death and heart failure following a myocardial infarction. Similarly other biomarkers such as Mid-regional pro-Atrial Natriuretic Peptide, ST2, C-Terminal pro-endothelin 1, Mid-regional pro-Adrenomedullin and copeptin all provide incremental information in predicting death and heart failure. Growth differentiation factor-15 and high-sensitivity C-reactive protein predict death following an acute coronary syndrome. Pregnancy associated plasma protein A levels following chest pain predicts risk of myocardial infarction and revascularisation. Some biomarkers such as myeloperoxidase and high-sensitivity C-reactive protein in an apparently healthy population predicts risk of coronary disease and allows clinicians to initiate early preventative treatment. In addition to biomarkers, various well-validated scoring systems based on clinical characteristics are available to help clinicians predict mortality risk, such as the Thrombolysis In Myocardial Infarction score and Global Registry of Acute Coronary Events score. A multimarker approach incorporating biomarkers and clinical scores will increase the prognostic accuracy. However, it is important to note that only troponin has been used to direct therapeutic intervention and none of the new prognostic biomarkers have been tested and proven to alter outcome of therapeutic intervention.

Novel biomarkers have improved prediction of outcome in acute myocardial infarction, but none have been demonstrated to alter the outcome of a particular therapy or management strategy. Randomised trials are urgently needed to address this translational gap before the use of novel biomarkers becomes common practice to facilitate tailored treatment following an acute coronary event.

Available only for authorised users

Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mahonen M, Cepaitis Z, Kuulasmaa K, Keil U: Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet. 2000, 355: 688-700. 10.1016/S0140-6736(99)11181-4.PubMed

Biological Markers - MeSH Result. [http://www.ncbi.nlm.nih.gov/mesh/68015415?ordinalpos=1&itool=EntrezSystem2.PEntrez.Mesh.Mesh_ResultsPanel.Mesh_RVDocSum]

Thygesen K, Alpert JS, White HD: Universal definition of myocardial infarction. J Am Coll Cardiol. 2007, 50: 2173-2195. 10.1016/j.jacc.2007.09.011.PubMed

Vasan RS: Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006, 113: 2335-2362. 10.1161/CIRCULATIONAHA.104.482570.PubMed

WHO Expert Committee on Diabetes Mellitus: Second report. World Health Organ Tech Rep Ser. 1980, 646: 1-80.

Alpert JS, Thygesen K, Antman E, Bassand JP: Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000, 36: 959-969. 10.1016/S0735-1097(00)00804-4.PubMed

Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E: Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996, 335: 1342-1349. 10.1056/NEJM199610313351802.PubMed

Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, Bickel C, Baldus S, Warnholtz A, Frohlich M, Sinning CR, Eleftheriadis MS, Wild PS, Schnabel RB, Lubos E, Jachmann N, Genth-Zotz S, Post F, Nicaud V, Tiret L, Lackner KJ, Münzel TF, Blankenberg S: Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med. 2009, 361: 868-877. 10.1056/NEJMoa0903515.PubMed

Itoi K, Jiang YQ, Iwasaki Y, Watson SJ: Regulatory mechanisms of corticotropin-releasing hormone and vasopressin gene expression in the hypothalamus. J Neuroendocrinol. 2004, 16: 348-355. 10.1111/j.0953-8194.2004.01172.x.PubMed

10.

Goldsmith SR: Vasopressin as Vasopressor. American Journal of Medicine. 1987, 82: 1213-1219. 10.1016/0002-9343(87)90228-2.PubMed

11.

Fukuzawa J, Haneda T, Kikuchi K: Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol Cell Biochem. 1999, 195: 93-98. 10.1023/A:1006980517557.PubMed

12.

Gheorghiade M, Gattis WA, O'Connor CM, Adams KF, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C, Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004, 291: 1963-1971. 10.1001/jama.291.16.1963.PubMed

13.

Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW: Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol. 2006, 47: 1615-1621. 10.1016/j.jacc.2005.11.071.PubMed

14.

Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG, Bergmann A, Potocki M, Noveanu M, Breidthardt T, Christ A, Boldanova T, Merki R, Schaub N, Bingisser R, Christ M, Mueller C: Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol. 2009, 54: 60-68. 10.1016/j.jacc.2009.01.076.PubMed

15.

Jochberger S, Morgenthaler NG, Mayr VD, Luckner G, Wenzel V, Ulmer H, Schwarz S, Hasibeder WR, Friesenecker BE, Dunser MW: Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab. 2006, 91: 4381-4386. 10.1210/jc.2005-2830.PubMed

16.

Glatz JF, Luiken JJ, van Nieuwenhoven FA, Van der Vusse GJ: Molecular mechanism of cellular uptake and intracellular translocation of fatty acids. Prostaglandins Leukot Essent Fatty Acids. 1997, 57: 3-9. 10.1016/S0952-3278(97)90485-3.PubMed

17.

Glatz JF, van Bilsen M, Paulussen RJ, Veerkamp JH, van der Vusse GJ, Reneman RS: Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox. Biochim Biophys Acta. 1988, 961: 148-152.PubMed

18.

Chan CP, Sanderson JE, Glatz JF, Cheng WS, Hempel A, Renneberg R: A superior early myocardial infarction marker. Human heart-type fatty acid-binding protein. Z Kardiol. 2004, 93: 388-397. 10.1007/s00392-004-0080-6.PubMed

19.

Chen L, Guo X, Yang F: Role of heart-type fatty acid binding protein in early detection of acute myocardial infarction in comparison with cTnI, CK-MB and myoglobin. J Huazhong Univ Sci Technolog Med Sci. 2004, 24: 449-451. 459PubMed

20.

Body R: Towards evidence based emergency medicine: Best BETs from the Manchester Royal Infirmary. Bet 2. Heart Fatty Acid binding protein for rapid diagnosis of acute myocardial infarction in the emergency department. Emerg Med J. 2009, 26: 519-522. 10.1136/emj.2009.076182.PubMed

21.

O'Donoghue M, de Lemos JA, Morrow DA, Murphy SA, Buros JL, Cannon CP, Sabatine MS: Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation. 2006, 114: 550-557. 10.1161/CIRCULATIONAHA.106.641936.PubMed

22.

Kilcullen N, Viswanathan K, Das R, Morrell C, Farrin A, Barth JH, Hall AS: Heart-type fatty acid-binding protein predicts long-term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values. J Am Coll Cardiol. 2007, 50: 2061-2067. 10.1016/j.jacc.2007.08.021.PubMed

23.

de Araujo Goncalves P, Ferreira J, Aguiar C, Seabra-Gomes R: TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J. 2005, 26: 865-872. 10.1093/eurheartj/ehi187.PubMed

24.

Scirica BM, Cannon CP, Antman EM, Murphy SA, Morrow DA, Sabatine MS, McCabe CH, Gibson CM, Braunwald E: Validation of the thrombolysis in myocardial infarction (TIMI) risk score for unstable angina pectoris and non-ST-elevation myocardial infarction in the TIMI III registry. Am J Cardiol. 2002, 90: 303-305. 10.1016/S0002-9149(02)02468-2.PubMed

25.

Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML: Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation. 2000, 101: 2557-2567.PubMed

26.

Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van De Werf F, Avezum A, Goodman SG, Flather MD, Fox KA: Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003, 163: 2345-2353. 10.1001/archinte.163.19.2345.PubMed

27.

Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med. 1998, 339: 321-328. 10.1056/NEJM199807303390507.PubMed

28.

de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001, 345: 1014-1021. 10.1056/NEJMoa011053.PubMed

29.

Arakawa N, Nakamura M, Aoki H, Hiramori K: Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. J Am Coll Cardiol. 1996, 27: 1656-1661. 10.1016/0735-1097(96)00067-8.PubMed

30.

Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, Sundsfjord JA, Dickstein K: Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996, 93: 1963-1969.PubMed

31.

Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M: Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med. 2004, 42: 942-944. 10.1515/CCLM.2004.153.PubMed

32.

Luckenbill KN, Christenson RH, Jaffe AS, Mair J, Ordonez-Llanos J, Pagani F, Tate J, Wu AH, Ler R, Apple FS: Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin Chem. 2008, 54: 619-621. 10.1373/clinchem.2007.097998.PubMed

33.

Lorgis L, Zeller M, Dentan G, Sicard P, Buffet P, L'Huillier I, Beer JC, Vincent-Martin M, Makki H, Gambert P, Cottin Y: Prognostic value of N-terminal pro-brain natriuretic peptide in elderly people with acute myocardial infarction: prospective observational study. BMJ. 2009, 338: b1605-10.1136/bmj.b1605.PubMedPubMedCentral

34.

Khan SQ, Narayan H, Ng KH, Dhillon OS, Kelly D, Quinn P, Squire IB, Davies JE, Ng LL: N-terminal pro-B-type natriuretic peptide complements the GRACE risk score in predicting early and late mortality following acute coronary syndrome. Clin Sci (Lond). 2009, 117: 31-39. 10.1042/CS20080419.

35.

Morrow DA, de Lemos JA, Sabatine MS, Murphy SA, Demopoulos LA, DiBattiste PM, McCabe CH, Gibson CM, Cannon CP, Braunwald E: Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol. 2003, 41: 1264-1272. 10.1016/S0735-1097(03)00168-2.PubMed

36.

Jernberg T, Lindahl B, Siegbahn A, Andren B, Frostfeldt G, Lagerqvist B, Stridsberg M, Venge P, Wallentin L: N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol. 2003, 42: 1909-1916. 10.1016/j.jacc.2003.07.015.PubMed

37.

Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, Hartford M, Caidahl K: N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002, 106: 2913-2918. 10.1161/01.CIR.0000041661.63285.AE.PubMed

38.

Bazzino O, Fuselli JJ, Botto F, Perez De Arenaza D, Bahit C, Dadone J: Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Eur Heart J. 2004, 25: 859-866. 10.1016/j.ehj.2004.03.004.PubMed

39.

Khan SQ, Quinn P, Davies JE, Ng LL: N-terminal pro-B-type natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction. Heart. 2008, 94: 40-43. 10.1136/hrt.2006.108985.PubMed

40.

Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW: Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 1998, 97: 1921-1929.PubMed

41.

Squire IB, O'Brien RJ, Demme B, Davies JE, Ng LL: N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. Clin Sci (Lond). 2004, 107: 309-316. 10.1042/CS20040087.

42.

Morgenthaler NG, Struck J, Thomas B, Bergmann A: Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem. 2004, 50: 234-236. 10.1373/clinchem.2003.021204.PubMed

43.

Ala-Kopsala M, Magga J, Peuhkurinen K, Leipala J, Ruskoaho H, Leppaluoto J, Vuolteenaho O: Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem. 2004, 50: 1576-1588. 10.1373/clinchem.2004.032490.PubMed

44.

Khan SQ, Dhillon O, Kelly D, Squire IB, Struck J, Quinn P, Morgenthaler NG, Bergmann A, Davies JE, Ng LL: Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol. 2008, 51: 1857-1864. 10.1016/j.jacc.2008.01.041.PubMed

45.

Wang J, Xu N, Feng X, Hou N, Zhang J, Cheng X, Chen Y, Zhang Y, Yang X: Targeted disruption of Smad4 in cardiomyocytes results in cardiac hypertrophy and heart failure. Circ Res. 2005, 97: 821-828. 10.1161/01.RES.0000185833.42544.06.PubMed

46.

Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, Lindahl B, Horn-Wichmann R, Brabant G, Simoons ML, Armstrong PW, Califf RM, Drexler H, Wallentin L: Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007, 115: 962-971. 10.1161/CIRCULATIONAHA.106.650846.PubMed

47.

Wollert KC, Kempf T, Lagerqvist B, Lindahl B, Olofsson S, Allhoff T, Peter T, Siegbahn A, Venge P, Drexler H, Wallentin L: Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation. 2007, 116: 1540-1548. 10.1161/CIRCULATIONAHA.107.697714.PubMed

48.

Kempf T, Bjorklund E, Olofsson S, Lindahl B, Allhoff T, Peter T, Tongers J, Wollert KC, Wallentin L: Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J. 2007, 28: 2858-2865. 10.1093/eurheartj/ehm465.PubMed

49.

Khan SQ, Ng K, Dhillon O, Kelly D, Quinn P, Squire IB, Davies JE, Ng LL: Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J. 2009, 30: 1057-1065. 10.1093/eurheartj/ehn600.PubMed

50.

Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, Rouleau JL, Lee RT: Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002, 106: 2961-2966. 10.1161/01.CIR.0000038705.69871.D9.PubMedPubMedCentral

51.

Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, Lee RT: Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004, 109: 2186-2190. 10.1161/01.CIR.0000127958.21003.5A.PubMed

52.

Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT: IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007, 117: 1538-1549. 10.1172/JCI30634.PubMedPubMedCentral

53.

Zhang SH, Reddick RL, Piedrahita JA, Maeda N: Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992, 258: 468-471. 10.1126/science.1411543.PubMed

54.

Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP, Gerszten RE, Lee RT: Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008, 117: 1936-1944. 10.1161/CIRCULATIONAHA.107.728022.PubMedPubMedCentral

55.

Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, Gannon J, Lee RT: Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009, 2: 684-691. 10.1161/CIRCHEARTFAILURE.109.873240.PubMed

56.

Oshikawa K, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Ohno S, Tominaga SI, Sugiyama Y: Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med. 2001, 164: 277-281.PubMed

57.

Kuroiwa K, Arai T, Okazaki H, Minota S, Tominaga S: Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun. 2001, 284: 1104-1108. 10.1006/bbrc.2001.5090.PubMed

58.

Diez J: Serum soluble ST2 as a biochemical marker of acute heart failure: future areas of research. J Am Coll Cardiol. 2008, 52: 1466-1467. 10.1016/j.jacc.2008.07.045.PubMed

59.

Khan SQ, Dhillon O, Struck J, Quinn P, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL: C-terminal pro-endothelin-1 offers additional prognostic information in patients after acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study. Am Heart J. 2007, 154: 736-742. 10.1016/j.ahj.2007.06.016.PubMed

60.

Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988, 332: 411-415. 10.1038/332411a0.PubMed

61.

Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, Masaki T: The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA. 1989, 86: 2863-2867. 10.1073/pnas.86.8.2863.PubMedPubMedCentral

62.

Haynes WG, Strachan FE, Webb DJ: Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation. 1995, 92: 357-363.PubMed

63.

Kurihara H, Yamaoki K, Nagai R, Yoshizumi M, Takaku F, Satoh H, Inui J, Yazaki Y: Endothelin: a potent vasoconstrictor associated with coronary vasospasm. Life Sci. 1989, 44: 1937-1943. 10.1016/0024-3205(89)90406-2.PubMed

64.

Cernacek P, Stewart DJ: Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. Biochem Biophys Res Commun. 1989, 161: 562-567. 10.1016/0006-291X(89)92636-3.PubMed

65.

Stewart DJ, Kubac G, Costello KB, Cernacek P: Increased plasma endothelin-1 in the early hours of acute myocardial infarction. J Am Coll Cardiol. 1991, 18: 38-43. 10.1016/S0735-1097(10)80214-1.PubMed

66.

Tomoda H: Plasma endothelin-1 in acute myocardial infarction with heart failure. Am Heart J. 1993, 125: 667-672. 10.1016/0002-8703(93)90155-3.PubMed

67.

Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T: Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993, 192: 553-560. 10.1006/bbrc.1993.1451.PubMed

68.

Sugo S, Minamino N, Kangawa K, Miyamoto K, Kitamura K, Sakata J, Eto T, Matsuo H: Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun. 1994, 201: 1160-1166. 10.1006/bbrc.1994.1827.PubMed

69.

Takahashi K, Satoh F, Hara E, Sone M, Murakami O, Kayama T, Yoshimoto T, Shibahara S: Production and secretion of adrenomedullin from glial cell tumors and its effects on cAMP production. Peptides. 1997, 18: 1117-1124. 10.1016/S0196-9781(97)00186-1.PubMed

70.

Lainchbury JG, Cooper GJ, Coy DH, Jiang NY, Lewis LK, Yandle TG, Richards AM, Nicholls MG: Adrenomedullin: a hypotensive hormone in man. Clin Sci (Lond). 1997, 92: 467-472.

71.

Parkes DG, May CN: ACTH-suppressive and vasodilator actions of adrenomedullin in conscious sheep. J Neuroendocrinol. 1995, 7: 923-929. 10.1111/j.1365-2826.1995.tb00737.x.PubMed

72.

Vari RC, Adkins SD, Samson WK: Renal effects of adrenomedullin in the rat. Proc Soc Exp Biol Med. 1996, 211: 178-183.PubMed

73.

Jougasaki M, Rodeheffer RJ, Redfield MM, Yamamoto K, Wei CM, McKinley LJ, Burnett JC: Cardiac secretion of adrenomedullin in human heart failure. J Clin Invest. 1996, 97: 2370-2376. 10.1172/JCI118680.PubMedPubMedCentral

74.

Kato J, Kobayashi K, Etoh T, Tanaka M, Kitamura K, Imamura T, Koiwaya Y, Kangawa K, Eto T: Plasma adrenomedullin concentration in patients with heart failure. J Clin Endocrinol Metab. 1996, 81: 180-183. 10.1210/jc.81.1.180.PubMed

75.

Jougasaki M, Wei CM, McKinley LJ, Burnett JC: Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation. 1995, 92: 286-289.PubMed

76.

Nakamura M, Yoshida H, Makita S, Arakawa N, Niinuma H, Hiramori K: Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. Circulation. 1997, 95: 1214-1221.PubMed

77.

Parkes DG, May CN: Direct cardiac and vascular actions of adrenomedullin in conscious sheep. Br J Pharmacol. 1997, 120: 1179-1185. 10.1038/sj.bjp.0701034.PubMedPubMedCentral

78.

Khan SQ, O'Brien RJ, Struck J, Quinn P, Morgenthaler N, Squire I, Davies J, Bergmann A, Ng LL: Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol. 2007, 49: 1525-1532. 10.1016/j.jacc.2006.12.038.PubMed

79.

Khan SQ, Dhillon OS, O'Brien RJ, Struck J, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL: C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation. 2007, 115: 2103-2110. 10.1161/CIRCULATIONAHA.106.685503.PubMed

80.

Kelly D, Squire IB, Khan SQ, Quinn P, Struck J, Morgenthaler NG, Davies JE, Ng LL: C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail. 2008, 14: 739-745. 10.1016/j.cardfail.2008.07.231.PubMed

81.

Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003, 107: 363-369. 10.1161/01.CIR.0000053730.47739.3C.PubMed

82.

Shishehbor MH, Bhatt DL, Topol EJ: Using C-reactive protein to assess cardiovascular disease risk. Cleve Clin J Med. 2003, 70: 634-640. 10.3949/ccjm.70.7.634.PubMed

83.

Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000, 102: 2165-2168.PubMed

84.

Nakajima T, Schulte S, Warrington KJ, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM: T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation. 2002, 105: 570-575. 10.1161/hc0502.103348.PubMed

85.

Nakagomi A, Freedman SB, Geczy CL: Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation. 2000, 101: 1785-1791.PubMed

86.

Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002, 106: 913-919. 10.1161/01.CIR.0000029802.88087.5E.PubMed

87.

Devaraj S, Xu DY, Jialal I: C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003, 107: 398-404. 10.1161/01.CIR.0000052617.91920.FD.PubMed

88.

Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E: C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005, 352: 20-28. 10.1056/NEJMoa042378.PubMed

89.

Suleiman M, Khatib R, Agmon Y, Mahamid R, Boulos M, Kapeliovich M, Levy Y, Beyar R, Markiewicz W, Hammerman H, Aronson D: Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol. 2006, 47: 962-968. 10.1016/j.jacc.2005.10.055.PubMed

90.

Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, Ogawa S: C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation. 1997, 96: 778-784.PubMed

91.

Matsui S, Ishii J, Kitagawa F, Kuno A, Hattori K, Ishikawa M, Okumura M, Kan S, Nakano T, Naruse H, Tanaka I, Nomura M, Hishida H, Ozaki Y: Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis. 2010, 210: 220-5. 10.1016/j.atherosclerosis.2009.10.033.PubMed

92.

de Servi S, Mazzone A, Ricevuti G, Mazzucchelli I, Fossati G, Angoli L, Valentini P, Boschetti E, Specchia G: Expression of neutrophil and monocyte CD11B/CD18 adhesion molecules at different sites of the coronary tree in unstable angina pectoris. Am J Cardiol. 1996, 78: 564-568. 10.1016/S0002-9149(96)00367-0.PubMed

93.

Dinerman JL, Mehta JL, Saldeen TG, Emerson S, Wallin R, Davda R, Davidson A: Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction. J Am Coll Cardiol. 1990, 15: 1559-1563. 10.1016/0735-1097(90)92826-N.PubMed

94.

Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A: Widespread coronary inflammation in unstable angina. N Engl J Med. 2002, 347: 5-12. 10.1056/NEJMoa012295.PubMed

95.

Davies MJ, Thomas A: Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med. 1984, 310: 1137-1140.PubMed

96.

Naruko T, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, Komatsu R, Ikura Y, Ogami M, Shimada Y, Ehara S, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker AE: Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002, 106: 2894-2900. 10.1161/01.CIR.0000042674.89762.20.PubMed

97.

Biasucci LM, D'Onofrio G, Liuzzo G, Zini G, Monaco C, Caligiuri G, Tommasi M, Rebuzzi AG, Maseri A: Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction, but its reduction is not related to ischemia. J Am Coll Cardiol. 1996, 27: 611-616. 10.1016/0735-1097(95)00524-2.PubMed

98.

Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, Simoons ML, Hamm CW: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003, 108: 1440-1445. 10.1161/01.CIR.0000090690.67322.51.PubMed

99.

Khan SQ, Kelly D, Quinn P, Davies JE, Ng LL: Myeloperoxidase aids prognostication together with N-terminal pro-B-type natriuretic peptide in high-risk patients with acute ST elevation myocardial infarction. Heart. 2007, 93: 826-831. 10.1136/hrt.2006.091041.PubMed

100.

Mocatta TJ, Pilbrow AP, Cameron VA, Senthilmohan R, Frampton CM, Richards AM, Winterbourn CC: Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol. 2007, 49: 1993-2000. 10.1016/j.jacc.2007.02.040.PubMed

101.

Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001, 286: 2136-2142. 10.1001/jama.286.17.2136.PubMed

102.

Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM: Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007, 50: 159-165. 10.1016/j.jacc.2007.03.033.PubMed

103.

Laursen LS, Overgaard MT, Nielsen CG, Boldt HB, Hopmann KH, Conover CA, Sottrup-Jensen L, Giudice LC, Oxvig C: Substrate specificity of the metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) assessed by mutagenesis and analysis of synthetic peptides: substrate residues distant from the scissile bond are critical for proteolysis. Biochem J. 2002, 367: 31-40. 10.1042/BJ20020831.PubMedPubMedCentral

104.

Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR, Virmani R, Oxvig C, Schwartz RS: Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med. 2001, 345: 1022-1029. 10.1056/NEJMoa003147.PubMed

105.

Lund J, Qin QP, Ilva T, Pettersson K, Voipio-Pulkki LM, Porela P, Pulkki K: Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation. 2003, 108: 1924-1926. 10.1161/01.CIR.0000096054.18485.07.PubMed

106.

Bayes-Genis A, Conover CA, Schwartz RS: The insulin-like growth factor axis: A review of atherosclerosis and restenosis. Circ Res. 2000, 86: 125-130.PubMed

107.

Beaudeux JL, Burc L, Imbert-Bismut F, Giral P, Bernard M, Bruckert E, Chapman MJ: Serum plasma pregnancy-associated protein A: a potential marker of echogenic carotid atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk. Arterioscler Thromb Vasc Biol. 2003, 23: e7-10. 10.1161/01.ATV.0000047448.76485.B8.PubMed

108.

Kelly D, Khan SQ, Thompson M, Cockerill G, Ng LL, Samani N, Squire IB: Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J. 2008.

109.

Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, Samani NJ, Squire IB: Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J. 2007, 28: 711-718. 10.1093/eurheartj/ehm003.PubMedPubMedCentral

110.

Dhillon OS, Khan SQ, Narayan HK, Ng KH, Mohammed N, Quinn PA, Squire IB, Davies JE, Ng LL: Matrix metalloproteinase-2 predicts mortality in patients with acute coronary syndrome. Clin Sci (Lond). 2009, 118: 249-57. 10.1042/CS20090226.

111.

Kelly D, Khan S, Cockerill G, Ng LL, Thompson M, Samani NJ, Squire IB: Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail. 2008, 10: 133-139. 10.1016/j.ejheart.2007.12.009.PubMedPubMedCentral

112.

Steinhart B, Thorpe KE, Bayoumi AM, Moe G, Januzzi JL, Mazer CD: Improving the diagnosis of acute heart failure using a validated prediction model. J Am Coll Cardiol. 2009, 54: 1515-1521. 10.1016/j.jacc.2009.05.065.PubMed

113.

Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S, Wagner B, Pacher R: N-terminal pro-b-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure: a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol. 55: 645-653. 10.1016/j.jacc.2009.08.078.

114.

Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, McCabe C, Antman EM, Cannon CP, Braunwald E: Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002, 105: 1760-1763. 10.1161/01.CIR.0000015464.18023.0A.PubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1741-7015/8/34/prepub

Title: Biomarkers in acute myocardial infarction
Authors: Daniel Chan
Leong L Ng
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: BMC Medicine / Issue 1/2010
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/1741-7015-8-34

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Biomarkers in acute myocardial infarction

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Incidence, detection, and tumour stage of breast cancer in a cohort of Italian women with negative screening mammography report recommending early (short-interval) rescreen

A functional polymorphism in the DNA methyltransferase-3A promoter modifies the susceptibility in gastric cancer but not in esophageal carcinoma

Blood cell gene expression associated with cellular stress defense is modulated by antioxidant-rich food in a randomised controlled clinical trial of male smokers

Reporting methods in studies developing prognostic models in cancer: a review

Enhancement drugs: are there limits to what we should enhance and why?

What is a clinical pathway? Development of a definition to inform the debate